TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

The U.S. Food and Drug Administration (FDA) has approved the drug capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a genetic mutation that results in the loss of exon 14 of the MET (mesenchymal-epithelial transition gene) gene.
The approval was based on a trial of 160 patients with metastatic NSCLC who had the mutation. Among previously untreated patients, the overall response rate (ORR) was 68% with a duration of response (DOR) of 16.6 months while in previously treated patients the ORR was 44% and the DOR was 9.7 months.
Even so, this new therapy will give hope to patients with this disease.

Download the article